Comment
doi: 10.1016/S0140-6736(21)02018-3.
Aspirin versus clopidogrel after percutaneous coronary intervention
Affiliations
- PMID: 34742380
- DOI: 10.1016/S0140-6736(21)02018-3
Item in Clipboard
Comment
Aspirin versus clopidogrel after percutaneous coronary intervention
Lancet.
.
No abstract available
Conflict of interest statement
MP has received advisory board fees from AstraZeneca and Janssen-Cilag, and speaker honorarium fees from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen-Cilag. CB declares no competing interests.
Comment in
-
Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply.Lancet. 2021 Nov 6;398(10312):1685-1686. doi: 10.1016/S0140-6736(21)02016-X. Lancet. 2021. PMID: 34742381 No abstract available.
Comment on
-
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.Lancet. 2021 Jun 26;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Epub 2021 May 16. Lancet. 2021. PMID: 34010616 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
